Biologics Competition Act of 2023

118 HR 1790 IH: Biologics Competition Act of 2023 U.S. House of Representatives 2023-03-24 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 118th CONGRESS 1st Session H. R. 1790 IN THE HOUSE OF REPRESENTATIVES March 24, 2023 Mrs. Miller-Meeks (for herself, Ms. Barragán , Mr. Murphy , and Ms. Kuster ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes. 1. Short title This Act may be cited as the Biologics Competition Act of 2023 . 2. Study on the substitution of interchangeable biological products Not later than 12 months after the date of enactment of this Act, the Secretary of Health and Human Services shall— (1) complete a study to evaluate the extent to which the substitution of interchangeable biological products licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) may be impacted by differences between the system for determining a biological product to be interchangeable under section 351(k)(4) of such Act ( 42 U.S.C. 262(k)(4) ) and the system for assigning therapeutic equivalence ratings to drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ); (2) submit a report to the Congress on the results of the study under paragraph (1); and (3) update the list published under section 351(k)(9)(A) of the Public Health Service Act ( 42 U.S.C. 262(k)(9)(A) ) (commonly referred to as the Purple Book ) to implement such changes as the Secretary deems necessary to harmonize the approach for communicating the substitutability of interchangeable biological products with the approach for communicating therapeutic equivalence ratings assigned to drugs, with the goals of— (A) minimizing any impediments to the substitution of interchangeable biological products; and (B) maintaining the distinct pathways by which biological products are licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) and drugs are approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ).